Clinical Trial Update: Tolerability and Efficacy of RJX in Patients With COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for RJX in COVID-19 patients reports tolerability and efficacy data across Phase 1 and Phase 2, with ongoing status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• RJX

Snippet

Sponsor: Reven Pharmaceuticals, Inc. | Conditions: COVID-19, Acute Respiratory Distress Syndrome | Phase 1, Phase 2 | Status: UNKNOWN